DARS2

Across TCGA pan-cancer cohorts, DARS2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DARS2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DARS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DARS2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, GBM, and LUAD are the cancer types where DARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.328	0.889	.014	8	view →
GBM	OS	Tertile	All	0.286	0.537	.008	4	view →
LUAD	DFS	Quartile	All	0.995	0.791	.023	3	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.249	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DARS2–HNSC (DFS)

Open the HNSC breakdown →